AR112403A1 - Formulaciones de ácidos nucleicos altamente concentradas - Google Patents
Formulaciones de ácidos nucleicos altamente concentradasInfo
- Publication number
- AR112403A1 AR112403A1 ARP180102225A AR112403A1 AR 112403 A1 AR112403 A1 AR 112403A1 AR P180102225 A ARP180102225 A AR P180102225A AR 112403 A1 AR112403 A1 AR 112403A1
- Authority
- AR
- Argentina
- Prior art keywords
- syndrome
- disease
- low viscosity
- nucleic acid
- acute
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 abstract 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000037157 Azotemia Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010063725 Idiopathic pneumonia syndrome Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 abstract 1
- 206010051895 acute chest syndrome Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000007915 ichthyosis prematurity syndrome Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica de baja viscosidad caracterizada porque comprende un ácido nucleico en una concentración de por lo menos 80 mg/ml. Reivindicación 33: Un dispositivo caracterizado porque es para la administración subcutánea de la formulación de baja viscosidad de cualquiera de las reivindicaciones precedentes. Reivindicación 34: Un método para tratar una enfermedad caracterizado porque comprende administrar la formulación de baja viscosidad de cualquiera de las reivindicaciones 1 - 33, donde la enfermedad se selecciona entre: trombosis, complicaciones relacionadas con transplante de células madre hematopoyéticas (HSCT) incluyendo al síndrome de obstrucción sinusoidal o a la enfermedad vasooclusiva hepática (VOD), enfermedad de injerto contra huésped (GvHD), microangiopatía trombótica asociada a transplante (TA-TMA) o síndrome de neumonía idiopática, otras TMAs que incluyen púrpura trombocitopénica trombótica (TTP) y síndrome urémico hemolítico (HUS), isquemia miocárdica aguda, ACV isquémico, lesión por reperfusión isquémica en el transplante de órganos sólidos, síndrome de dificultad respiratoria aguda (ARDS), crisis vasooclusiva de células falciformes (VOC), síndrome torácico agudo relacionado con células falciformes, coagulación intravascular diseminada (DIC), septicemia, insuficiencia renal, otras enfermedades coronaras o de las arterias periféricas, formas malignas hematológicas o tumores sólidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540657P | 2017-08-03 | 2017-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112403A1 true AR112403A1 (es) | 2019-10-23 |
Family
ID=63364168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102225 AR112403A1 (es) | 2017-08-03 | 2018-08-03 | Formulaciones de ácidos nucleicos altamente concentradas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200261489A1 (es) |
| EP (1) | EP3661484A1 (es) |
| JP (1) | JP2020530004A (es) |
| KR (1) | KR20200121780A (es) |
| CN (1) | CN111132663A (es) |
| AR (1) | AR112403A1 (es) |
| AU (1) | AU2018309068A1 (es) |
| BR (1) | BR112020002289A2 (es) |
| CA (1) | CA3071544A1 (es) |
| CO (1) | CO2020001873A2 (es) |
| IL (1) | IL272405A (es) |
| MX (1) | MX2020001337A (es) |
| SG (1) | SG11202000952PA (es) |
| TW (1) | TW201909904A (es) |
| WO (1) | WO2019028340A1 (es) |
| ZA (1) | ZA202000676B (es) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201408481UA (en) | 2012-06-22 | 2015-01-29 | Gentium Spa | Euglobulin-based method for determining the biological activity of defibrotide |
| US20190328765A1 (en) | 2018-04-30 | 2019-10-31 | Gentium S.R.L. | Methods for treating patients having sinusoidal obstruction syndrome |
| WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| WO2021174039A1 (en) | 2020-02-28 | 2021-09-02 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| WO2021212055A1 (en) | 2020-04-17 | 2021-10-21 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
| KR20220151414A (ko) * | 2021-05-06 | 2022-11-15 | 연세대학교 산학협력단 | 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1043823B (it) | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
| IT1170214B (it) | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US4693134A (en) | 1985-06-20 | 1987-09-15 | Excelermatic Inc. | High-powered vehicle drive train |
| IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1223322B (it) | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| IT1231509B (it) | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US5977083A (en) | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| US6699985B2 (en) | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| IT1252174B (it) | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| ATE311907T1 (de) | 1999-06-08 | 2005-12-15 | Gentium Spa | Anwendung von komplexen von kationischen liposomen und polydeoxyribonukleotiden wie arzneimitteln |
| US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
| EP1325962A1 (en) | 2001-12-17 | 2003-07-09 | Gentium S.p.A. | A method for determining the biological activity of defibrotide |
| ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| WO2005089503A2 (en) * | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
| AU2006222044A1 (en) | 2005-03-03 | 2006-09-14 | Gentium Spa | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| EP1872787A1 (en) | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| CN101301308A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防弥散性血管内凝血药物中的应用 |
| CN101301306A (zh) * | 2008-06-30 | 2008-11-12 | 广东天普生化医药股份有限公司 | Dft在制备治疗和预防休克药物中的应用 |
| CN101759767A (zh) | 2008-10-23 | 2010-06-30 | 湖州来色生物基因工程有限公司 | 一种双甘氨肽的合成方法 |
| CN102946861B (zh) * | 2010-03-01 | 2016-01-20 | 西托戴恩有限公司 | 浓缩蛋白制剂及其用途 |
| CN107007617A (zh) | 2010-11-12 | 2017-08-04 | 真蒂奥姆责任有限公司 | 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd) |
| SG11201408481UA (en) | 2012-06-22 | 2015-01-29 | Gentium Spa | Euglobulin-based method for determining the biological activity of defibrotide |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
-
2018
- 2018-08-03 AR ARP180102225 patent/AR112403A1/es unknown
- 2018-08-03 AU AU2018309068A patent/AU2018309068A1/en not_active Abandoned
- 2018-08-03 CA CA3071544A patent/CA3071544A1/en not_active Abandoned
- 2018-08-03 WO PCT/US2018/045152 patent/WO2019028340A1/en not_active Ceased
- 2018-08-03 EP EP18759469.2A patent/EP3661484A1/en not_active Withdrawn
- 2018-08-03 MX MX2020001337A patent/MX2020001337A/es unknown
- 2018-08-03 KR KR1020207006232A patent/KR20200121780A/ko not_active Withdrawn
- 2018-08-03 TW TW107127108A patent/TW201909904A/zh unknown
- 2018-08-03 SG SG11202000952PA patent/SG11202000952PA/en unknown
- 2018-08-03 BR BR112020002289-6A patent/BR112020002289A2/pt not_active Application Discontinuation
- 2018-08-03 JP JP2020506213A patent/JP2020530004A/ja active Pending
- 2018-08-03 CN CN201880061131.7A patent/CN111132663A/zh active Pending
- 2018-08-20 US US16/105,319 patent/US20200261489A1/en not_active Abandoned
-
2020
- 2020-01-31 ZA ZA2020/00676A patent/ZA202000676B/en unknown
- 2020-02-02 IL IL272405A patent/IL272405A/en unknown
- 2020-02-20 CO CONC2020/0001873A patent/CO2020001873A2/es unknown
-
2021
- 2021-07-16 US US17/377,972 patent/US20210338707A1/en not_active Abandoned
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201909904A (zh) | 2019-03-16 |
| US20200261489A1 (en) | 2020-08-20 |
| ZA202000676B (en) | 2021-01-27 |
| BR112020002289A2 (pt) | 2020-07-28 |
| AU2018309068A1 (en) | 2020-02-20 |
| WO2019028340A1 (en) | 2019-02-07 |
| EP3661484A1 (en) | 2020-06-10 |
| WO2019028340A9 (en) | 2019-08-08 |
| US20210338707A1 (en) | 2021-11-04 |
| AU2018309068A8 (en) | 2020-02-27 |
| CA3071544A1 (en) | 2019-02-07 |
| JP2020530004A (ja) | 2020-10-15 |
| CN111132663A (zh) | 2020-05-08 |
| MX2020001337A (es) | 2020-09-09 |
| SG11202000952PA (en) | 2020-02-27 |
| KR20200121780A (ko) | 2020-10-26 |
| IL272405A (en) | 2020-03-31 |
| CO2020001873A2 (es) | 2020-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112403A1 (es) | Formulaciones de ácidos nucleicos altamente concentradas | |
| AR081679A1 (es) | Metodos y composiciones para la administracion intratecal de heparan n-sulfatasa, envase | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| PE20080658A1 (es) | Formulaciones de metilnaltrexona en forma de polvo seco | |
| CL2019002513A1 (es) | Composiciones de limpieza cosmética. | |
| MX362382B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| RU2017125931A (ru) | Фармацевтическая композиция, содержащая плазминоген, и ее применение | |
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| AR083862A1 (es) | Producto de cuidado oral y metodo para su uso y fabricacion | |
| AR109799A1 (es) | Composición para el tratamiento del cabello | |
| AR095964A1 (es) | Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil | |
| HRP20201242T1 (hr) | Tekući farmaceutski pripravak | |
| MX2019007768A (es) | Composiciones que comprenden tensioactivos y metodos de uso de las composiciones. | |
| PE20230112A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria | |
| UY35905A (es) | Inhibidores del transporte de glucosa | |
| PE20212158A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso | |
| CO2022002545A2 (es) | Proteínas de fusión terapéuticas | |
| ES2577182T3 (es) | Alimento fermentado y método para la producción del mismo | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| MX2021014736A (es) | Identificacion y seleccion de un material de partida vegetal de sulfato de condroitina vegetal y acido hialuronico, y transformacion de dicho material de partida vegetal para obtener ingredientes para su uso en alimentos, suplementos, dispositivos medicos o medicamentos. | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
| AR080970A1 (es) | Uso de una composicion que contiene fosfolipidos para eliminar acumulaciones por lipolisis subcutanea | |
| PE20191793A1 (es) | Metodo para preparar una composicion con un bajo contenido de oxigeno disuelto, que comprende paracetamol, y opcionalmente uno o mas aine, y una composicion obtenida de la misma | |
| AR113066A1 (es) | Substituto de sal baja en sodio con cloruro de potasio | |
| MX2016016339A (es) | Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |